Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 56% Improvement Relative Risk ICU admission -59% Severe case -61% Siuka et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Prospective study of 301 patients in Slovenia (Dec 2020 - Dec 2021) Siuka et al., F1000Research, doi:10.12688/f1000research.131730.1 Favors vitamin D Favors control
The effect of Vitamin D levels on the course of COVID-19 in hospitalized patients – a 1-year prospective cohort study
Siuka et al., F1000Research, doi:10.12688/f1000research.131730.1
Siuka et al., The effect of Vitamin D levels on the course of COVID-19 in hospitalized patients – a 1-year prospective.., F1000Research, doi:10.12688/f1000research.131730.1
Mar 2023   Source   PDF  
  All Studies   Meta
Prospective study of 301 hospitalized patients in Slovenia, showing higher mortality with vitamin D deficiency, without statistical significance. Fewer patients with severe cases were deficient, which authors hypothesize was due to their recommendations for supplementation - many patients reported initiating supplementation after symptoms started but before hospitalization (while asymptomatic patients did not initiate supplementation).
risk of death, 55.9% lower, RR 0.44, p = 0.24, high D levels (≥30nmol/L) 10 of 255 (3.9%), low D levels (<30nmol/L) 4 of 45 (8.9%), NNT 20.
risk of ICU admission, 58.8% higher, RR 1.59, p = 0.59, high D levels (≥30nmol/L) 27 of 255 (10.6%), low D levels (<30nmol/L) 3 of 45 (6.7%).
risk of severe case, 61.0% higher, RR 1.61, p = 0.009, high D levels (≥30nmol/L) 146 of 255 (57.3%), low D levels (<30nmol/L) 16 of 45 (35.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Siuka et al., 9 Mar 2023, prospective, Slovenia, peer-reviewed, 7 authors, study period December 2020 - December 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: F1000Research 2023, 12:254 Last updated: 09 MAR 2023 RESEARCH ARTICLE The effect of Vitamin D levels on the course of COVID-19 in hospitalized patients – a 1-year prospective cohort study [version 1; peer review: awaiting peer review] Darko Siuka1, Rajko Saletinger2,3, Jure Uršič1, Kristina Jevnikar4, Rado Janša1,2, David Štubljar 5, Joško Osredkar 6,7 1Department of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia 2Faculty of Medicine, University of Ljubljana, Ljubljana, 1000, Slovenia 3Department of Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia 4Department of Ophthalmology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia 5Research and Development, In-Medico, Metlika, 8330, Slovenia 6Institute of Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia 7Department of Clinical Biochemistry, Faculty of Pharmacy, Ljubjana, 1000, Slovenia v1 First published: 09 Mar 2023, 12:254 Latest published: 09 Mar 2023, 12:254 Open Peer Review Approval Status AWAITING PEER REVIEW Any reports and responses or comments on the Abstract Background: The aim of the current study was to assess the patients with COVID-19 and the impact of vitamin D supplementation on the course of COVID-19. Methods: This prospective cohort study included patients hospitalized due to COVID-19 between December 2020 and December 2021. Patients' demographic, clinical, and laboratory parameters were analysed. Results: 301 participants were enrolled in the study. 46 (15,3%) had moderate, and 162 (53,8%) had severe COVID-19. 14 (4,7%) patients died, and 30 (10,0%) were admitted to the ICU due to disease worsening. The majority needed oxygen therapy (n=224; 74,4%). Average vitamin 25(OH)D3 levels were below optimal at the admittance, and vitamin D deficiency was detected in 205 individuals. More male patients were suffering from vitamin D deficiency. Patients with the more severe disease showed lower levels of vitamin 25(OH)D3 in their blood. The most severe group of patients had more symptoms that lasted significantly longer with progressing disease severity. This group of patients also suffered from more deaths, ICU admissions, and treatments with dexamethasone, remdesivir, and oxygen. Conclusion: Patients with the severe course of COVID-19 were shown to have increased inflammatory parameters, increased mortality, and higher incidence of vitamin D deficiency. The results suggest that the vitamin D deficiency might represent a significant risk factor for a severe course of COVID-19. article can be found at the end of the article. Page 1 of 15 F1000Research 2023, 12:254 Last updated: 09 MAR 2023 Keywords vitamin D; COVID-19; severity; supplementation Corresponding author: Joško Osredkar ( Author roles: Siuka D: Conceptualization, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; Saletinger R: Formal Analysis; Uršič J: Data Curation, Investigation, Methodology; Jevnikar K: Data Curation, Investigation, Methodology; Janša R: Formal Analysis, Validation; Štubljar D: Data Curation, Formal Analysis, Investigation; Osredkar J: Conceptualization, Supervision, Writing – Review & Editing Competing interests: No competing interests were disclosed. Grant information: The author(s) declared..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop